Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 2 drugs with upcoming expirations
Pipeline
By Phase
1 drugs in development
By Therapeutic Area
top 1
R&D Momentum
18/100
Pipeline Velocity
0/100
Trial Completion Rate
100/100
Pipeline Concentration
100/100
Pipeline Freshness
89/100
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Regulatory
Triostat — CYTOMEL
Application NDA010379 (NDA)
Tapazole — TAPAZOLE
Application NDA007517 (NDA)
Metaxalone — SKELAXIN
Application NDA013217 (NDA)
Triostat — TRIOSTAT
Application NDA020105 (NDA)
Altace — ALTACE
Application NDA019901 (NDA)
Altace — ALTACE
Application NDA022021 (NDA)
Metaxalone — METAXALONE
Application NDA022503 (NDA)
Altace — VOSTALLY
Application NDA219757 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)